inotiv - NOTV

NOTV

Close Chg Chg %
3.21 0.20 6.23%

Closed Market

3.41

+0.20 (6.23%)

Volume: 755.63K

Last Updated:

Nov 21, 2024, 4:00 PM EDT

Company Overview: inotiv - NOTV

NOTV Key Data

Open

$3.20

Day Range

3.19 - 3.65

52 Week Range

1.23 - 11.42

Market Cap

$83.47M

Shares Outstanding

26.00M

Public Float

22.14M

Beta

3.37

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$3.84

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

398.59K

 

NOTV Performance

1 Week
 
27.24%
 
1 Month
 
99.42%
 
3 Months
 
118.59%
 
1 Year
 
20.07%
 
5 Years
 
-17.03%
 

NOTV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 2
Full Ratings ➔

About inotiv - NOTV

Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.

NOTV At a Glance

Inotiv, Inc.
2701 Kent Avenue
West Lafayette, Indiana 47906-1382
Phone 1-765-463-4527 Revenue 572.43M
Industry Miscellaneous Commercial Services Net Income -105,140,000.00
Sector Commercial Services 2023 Sales Growth 4.523%
Fiscal Year-end 09 / 2024 Employees 1,955
View SEC Filings

NOTV Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.138
Price to Book Ratio 0.295
Price to Cash Flow Ratio 2.832
Enterprise Value to EBITDA 8.798
Enterprise Value to Sales 0.804
Total Debt to Enterprise Value 0.907

NOTV Efficiency

Revenue/Employee 292,800.512
Income Per Employee -53,780.051
Receivables Turnover 6.331
Total Asset Turnover 0.629

NOTV Liquidity

Current Ratio 1.617
Quick Ratio 1.047
Cash Ratio 0.268

NOTV Profitability

Gross Margin 22.844
Operating Margin -0.416
Pretax Margin -21.705
Net Margin -18.367
Return on Assets -11.557
Return on Equity -33.403
Return on Total Capital -15.309
Return on Invested Capital -15.188

NOTV Capital Structure

Total Debt to Total Equity 155.168
Total Debt to Total Capital 60.81
Total Debt to Total Assets 48.76
Long-Term Debt to Equity 148.394
Long-Term Debt to Total Capital 58.155
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Inotiv - NOTV

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
60.47M 89.61M 547.66M 572.42M
Sales Growth
+38.64% +48.18% +511.19% +4.52%
Cost of Goods Sold (COGS) incl D&A
42.23M 59.45M 421.33M 441.66M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
4.98M 7.56M 49.32M 54.72M
Depreciation
4.28M 5.79M 18.44M 20.04M
Amortization of Intangibles
703.00K 1.77M 30.89M 34.68M
COGS Growth
+37.59% +40.77% +608.73% +4.83%
Gross Income
18.24M 30.16M 126.32M 130.76M
Gross Income Growth
+41.14% +65.36% +318.90% +3.51%
Gross Profit Margin
+30.16% +33.65% +23.07% +22.84%
2020 2021 2022 2023 5-year trend
SG&A Expense
19.85M 28.67M 122.10M 127.32M
Research & Development
- - 950.00K 405.00K
-
Other SG&A
18.90M 28.27M 122.10M 127.32M
SGA Growth
+51.84% +44.43% +325.85% +4.27%
Other Operating Expense
- - 1.30M 5.83M
-
Unusual Expense
1.45M (2.74M) 318.28M 72.22M
EBIT after Unusual Expense
(3.06M) 4.22M (315.36M) (74.60M)
Non Operating Income/Expense
15.00K 3.58M (7.39M) (6.62M)
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.49M 1.68M 29.70M 43.02M
Interest Expense Growth
+132.09% +12.95% +1,664.94% +44.83%
Gross Interest Expense
1.49M 1.68M 29.70M 43.02M
Interest Capitalized
- - - -
-
Pretax Income
(4.54M) 6.12M (352.45M) (124.24M)
Pretax Income Growth
-477.35% +234.84% -5,859.91% +64.75%
Pretax Margin
-7.50% +6.83% -64.36% -21.70%
Income Tax
147.00K (4.78M) (15.19M) (19.34M)
Income Tax - Current - Domestic
(25.00K) 7.00K 557.00K 5.46M
Income Tax - Current - Foreign
- - 1.67M 944.00K
-
Income Tax - Deferred - Domestic
172.00K (881.00K) (17.41M) (25.37M)
Income Tax - Deferred - Foreign
- (3.90M) (13.00K) (374.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(4.68M) 10.89M (337.26M) (104.90M)
Minority Interest Expense
- - (244.00K) 238.00K
-
Net Income
(4.68M) 10.89M (337.02M) (105.14M)
Net Income Growth
-493.04% +332.55% -3,193.33% +68.80%
Net Margin Growth
-7.75% +12.16% -61.54% -18.37%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(4.68M) 10.89M (337.02M) (105.14M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(4.68M) 10.89M (337.02M) (105.14M)
EPS (Basic)
-0.4318 0.8259 -13.8383 -4.1005
EPS (Basic) Growth
-467.41% +291.27% -1,775.54% +70.37%
Basic Shares Outstanding
10.85M 13.19M 24.35M 25.64M
EPS (Diluted)
-0.4318 0.7858 -13.8383 -4.1005
EPS (Diluted) Growth
-467.41% +281.98% -1,861.05% +70.37%
Diluted Shares Outstanding
10.85M 13.87M 24.35M 25.64M
EBITDA
3.37M 9.05M 52.25M 52.34M
EBITDA Growth
+31.24% +168.86% +477.52% +0.17%
EBITDA Margin
+5.56% +10.10% +9.54% +9.14%

Snapshot

Average Recommendation BUY Average Target Price 6.00
Number of Ratings 2 Current Quarters Estimate -0.67
FY Report Date 12 / 2024 Current Year's Estimate -2.62
Last Quarter’s Earnings -0.975 Median PE on CY Estimate N/A
Year Ago Earnings -4.435 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 1 1 2 N/A
Mean Estimate -0.67 -0.54 -2.62 N/A
High Estimates -0.67 -0.54 -2.24 N/A
Low Estimate -0.67 -0.54 -3.00 N/A
Coefficient of Variance N/A N/A -20.51 N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 1
OVERWEIGHT 0 0 0
HOLD 0 0 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Overweight

Insider Actions for Inotiv - NOTV

Date Name Shares Transaction Value
Aug 16, 2024 Robert W. Leasure President and CEO; Director 1,052,909 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Aug 16, 2024 Robert W. Leasure President and CEO; Director 300,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Inotiv in the News